I
Immunocore
TCR bispecific immunotherapies for cancer and infectious diseases
At a glance
- Founded
- 2008
- Headquarters
- Milton, United Kingdom
- Listing
- IPO 2021
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Latest news
Press, funding announcements and product moves mentioning Immunocore.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- ELEli Lilly
- WMWoodford Investment Management
- RIRTW Investments
Series B and later9 investors entered at this stage
- JFJDRF T1D Fund
- RCRock Springs Capital
General Atlantic- WVWuXi Healthcare Ventures
BlackRock- BFBill & Melinda Gates Foundation
- CICCB International
- OFOmega Funds
- UOUniversity of Oxford
Source: Dealroom Talent Intelligence.
Alumni founders
Former Immunocore employees who went on to found companies, sorted by Dealroom signal score.
Julian HirstUnited Kingdom
ADAdaptimmuneEst. 2008
Bent JakobsenUnited KingdomGlobal footprint
team presence
across markets
Patents
54 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immunocore on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immunocore on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.